Friday, 6 September 2024
Plenary Room: Paranimf

09:00 - 10:00 Welcome and Introduction
09:00 - 09:15 What is EBMT
09:15 - 09:30 What is WMDA
09:30 - 09:45 What is JACIE
09:45 - 10:00 Q&A

10:00 - 11:15 Session I: Basics to know
10:00 - 10:15 HLA-system
10:15 - 10:30 Role of germline predisposition
10:30 - 10:45 Donor selection and graft source
10:45 - 10:50 Case Presentation 1
10:50 - 11:15 Q&A

11:15 – 11:45 Coffee Break

11:45 - 13:00 Session II: Old but new?
11:45 - 12:00 Conditioning regimen and intensity
12:00 - 12:15 Engraftment, graft failure, poor graft function
12:15 - 12:30 Measurable residual disease
12:30 - 12:35 Case Presentation 2 (engraftment…)
12:35 - 12:40 Case Presentation 3 (MRD)
12:40 - 13:00 Q&A

13:00 – 13:45 Lunch Break

13:45 – 14:30 Industry Symposium
Further information soon

For further information contact education.events@ebmt.org
14:30 – 16:00  **Session III: Statistical and ethical considerations**

14:30 - 14:50  Statistics
14:50 - 15:10  Non-relapse mortality from patient perspective
15:10 - 15:30  Patient reported outcomes
15:30 - 15:45  Palliative care: when enough is enough?
15:45 - 16:00  Q&A

16:00 - 16:30  **Coffee Break**

16:30 - 18:00  **Session IV: GVHD**

16:30 - 16:45  Prophylaxis and diagnosis
16:45 - 17:00  Treatment of acute GVHD
17:00 - 17:15  Treatment of chronic GVHD
17:15 - 17:35  Q&A
17:35 - 17:40  Case presentation 4
17:40 - 17:45  Case Presentation 5
17:45 - 18:00  Q&A

18:15 - 19:45  **Poster Tour and Welcome Reception**
09:00 - 09:50 Session V: Indications for allogeneic HCT in Adults – Leukemia

09:00 - 09:25 Introductory Case-based AML - Discussion
09:25 - 09:50 Introductory Case-based ALL - Discussion

09:50 - 10:40 Session VI: Indications for allogeneic HCT in Adults – MDS and MPN

09:50 - 10:15 Introductory Case-based MDS – Discussion
10:15 - 10:40 Introductory Case-based MPN - Discussion

10:40 - 11:10 Coffee Break

11:10 - 12:30 Session VII: Challenging Cases in allogeneic HCT

11:10 - 11:30 Transplant for bone marrow failures
11:30 - 11:35 Case Presentation 6: BMF
11:35 - 11:50 Discussion
11:50 - 11:55 Case Presentation 7: AML/ALL
11:55 - 12:10 Discussion
12:10 - 12:15 Case Presentation 8: MPN/MDS
12:15 - 12:30 Discussion

12:30 – 13:15 Lunch Break

13:15 – 14:00 Industry Symposium

Further information soon
### 14:00 - 15:40  Session VIII: Indications for transplant and CAR-T

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:15</td>
<td>Multiple myeloma: Transplant</td>
</tr>
<tr>
<td>14:15 - 14:30</td>
<td>Multiple myeloma: CAR-T</td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td>Case Presentation 9</td>
</tr>
<tr>
<td>14:35 - 14:50</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>14:50 - 15:05</td>
<td>Lymphoma: Transplant</td>
</tr>
<tr>
<td>15:05 - 15:20</td>
<td>Lymphoma: CAR-T</td>
</tr>
<tr>
<td>15:20 - 15:25</td>
<td>Case Presentation 10</td>
</tr>
<tr>
<td>15:25 - 15:40</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

### 15:40 - 16:00  Coffee Break

### 16:00 - 17:00  Keynote Lectures

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:20</td>
<td>Current status of autologous HCT in AID</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td>Novel frontiers: CAR-T in AID</td>
</tr>
<tr>
<td>16:40 - 17:00</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>
09:00 – 10:20 Session I: Acute leukaemia in children

09:00 - 09:20  HSCT for AML in 2024- who, how and when?
09:20 - 09:50  Latest updates for HSCT in Paediatric ALL
09:50 - 10:10  Challenging cases in paediatric ALL-CAR-T and beyond
10:10 - 10:15  Case presentation 11
10:15 - 10:40  Q&A and discussion

10:40 – 11:10  Coffee Break

11:10 - 12:30 Session II: Inborn errors of metabolism

11:10 – 11:30  HSCT vs gene therapy for metabolic disease
11:30 – 11:50  Stem cell therapy for immune deficiency in 2024
11:50 – 12:10  HSCT for immune dysregulation
12:10 – 12:15  Case presentation 12
12:15 – 12:30  Discussion

12:30 – 13:15  Lunch Break

14:00 - 15:30 Session III: Haemoglobinopathies and bone marrow failure syndromes

14:00 – 14:20  HSCT vs gene therapy for haemoglobinopathy
14:20 – 14:40  Case-based approach to HSCT for congenital bone marrow failure syndromes
14:40 – 15:00  HSCT for paediatric MDS in 2024- who, how and when?
15:00 – 15:05  Case presentation 13
15:05 – 15:30  Discussion

For further information contact education.events@ebmt.org
## Preliminary Programme

### Sunday, 8 September 2024

**Plenary Room: Paranimf**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session IX: Endothelial and neurologic complications after HCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 09:15</td>
<td>VOD</td>
</tr>
<tr>
<td>09:15 - 09:30</td>
<td>TMA</td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td>Neurological complications (non-infectious)</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Long-term complications</td>
</tr>
<tr>
<td>10:15 - 10:20</td>
<td>Case Presentation 14</td>
</tr>
<tr>
<td>10:20 - 10:30</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

### 10:30 - 11:00  Coffee Break

### 11:00 - 12:30 Session X: Infections

<table>
<thead>
<tr>
<th>Time</th>
<th>Session X: Infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 - 11:15</td>
<td>CMV</td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td>Other Herpesviridae</td>
</tr>
<tr>
<td>11:30 - 11:45</td>
<td>Fungal</td>
</tr>
<tr>
<td>11:45 – 11:50</td>
<td>Case Presentation</td>
</tr>
<tr>
<td>11:50- 12:10</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

### 12:10 - 13:15 Session XI: Complications after CAR-T

<table>
<thead>
<tr>
<th>Time</th>
<th>Session XI: Complications after CAR-T</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:10 – 12:25</td>
<td>CRS &amp; ICANS</td>
</tr>
<tr>
<td>12:25 – 12:40</td>
<td>HLH &amp; MAS</td>
</tr>
<tr>
<td>12:40 – 12:45</td>
<td>Critical care management of BMT/CAR-T patients</td>
</tr>
<tr>
<td>12:45 - 13:00</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

### 13:15 - 13:30 Closing and Poster Awards

For further information contact education.events@ebmt.org